Kilitch Drugs (India) Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Kilitch Drugs (India).
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 17.4% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly
Mar 05
Kilitch Drugs (India) Limited (NSE:KILITCH) Looks Just Right With A 26% Price Jump
Feb 02We Ran A Stock Scan For Earnings Growth And Kilitch Drugs (India) (NSE:KILITCH) Passed With Ease
Jan 30Investors Shouldn't Be Too Comfortable With Kilitch Drugs (India)'s (NSE:KILITCH) Earnings
Nov 17Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why
Sep 23These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Sep 08Here's Why Kilitch Drugs (India) (NSE:KILITCH) Has Caught The Eye Of Investors
May 05Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt
Jul 06Here's Why I Think Kilitch Drugs (India) (NSE:KILITCH) Might Deserve Your Attention Today
Apr 08These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Dec 17Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?
Mar 21Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Feb 13Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?
Dec 03
Does Kilitch Drugs (India) Limited (NSE:KILITCH) Have A Place In Your Dividend Stock Portfolio?
Aug 20Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jul 16In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kilitch Drugs (India) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2023 | 1,550 | 146 | N/A | N/A | N/A |
| 9/30/2023 | 1,532 | 140 | -262 | -265 | N/A |
| 6/30/2023 | 1,427 | 117 | N/A | N/A | N/A |
| 3/31/2023 | 1,396 | 104 | -12 | 26 | N/A |
| 12/31/2022 | 1,307 | 98 | N/A | N/A | N/A |
| 9/30/2022 | 1,352 | 85 | 101 | 225 | N/A |
| 6/30/2022 | 1,281 | 83 | N/A | N/A | N/A |
| 3/31/2022 | 1,142 | 74 | -24 | 58 | N/A |
| 12/31/2021 | 976 | 52 | N/A | N/A | N/A |
| 9/30/2021 | 835 | 63 | 44 | 27 | N/A |
| 6/30/2021 | 780 | 62 | N/A | N/A | N/A |
| 3/31/2021 | 685 | 37 | 94 | 457 | N/A |
| 12/31/2020 | 602 | 17 | N/A | N/A | N/A |
| 9/30/2020 | 558 | 4 | -8 | 456 | N/A |
| 6/30/2020 | 531 | -3 | N/A | N/A | N/A |
| 3/31/2020 | 533 | 8 | -60 | 45 | N/A |
| 12/31/2019 | 609 | 26 | N/A | N/A | N/A |
| 9/30/2019 | 534 | -32 | N/A | N/A | N/A |
| 6/30/2019 | 648 | -3 | N/A | N/A | N/A |
| 3/31/2019 | 825 | 38 | -187 | 3 | N/A |
| 3/31/2018 | 510 | 52 | -21 | 14 | N/A |
| 3/31/2017 | 287 | -89 | N/A | 11 | N/A |
| 3/31/2016 | 210 | -112 | N/A | 172 | N/A |
| 3/31/2015 | 190 | -3 | N/A | -76 | N/A |
| 12/31/2014 | 222 | -8 | N/A | N/A | N/A |
| 9/30/2014 | 199 | 8 | N/A | N/A | N/A |
| 6/30/2014 | 168 | -1 | N/A | N/A | N/A |
| 3/31/2014 | 149 | 12 | N/A | -311 | N/A |
| 12/31/2013 | 151 | 35 | N/A | N/A | N/A |
| 9/30/2013 | 178 | 28 | N/A | N/A | N/A |
| 6/30/2013 | 214 | 22 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if KILITCH's forecast earnings growth is above the savings rate (6.7%).
Earnings vs Market: Insufficient data to determine if KILITCH's earnings are forecast to grow faster than the Indian market
High Growth Earnings: Insufficient data to determine if KILITCH's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if KILITCH's revenue is forecast to grow faster than the Indian market.
High Growth Revenue: Insufficient data to determine if KILITCH's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if KILITCH's Return on Equity is forecast to be high in 3 years time